Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H11ClN2O4S |
| Molecular Weight | 278.713 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2
InChI
InChIKey=KXSAIQPPGSSNKX-ZETCQYMHSA-N
InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11616111
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | |||
|
871824-55-4
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | |||
|
JNJ-26489112
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase. JNJ-26489112 is also being studied as a treatment for major depressive disorder. | ||
|
DB15203
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | |||
|
DTXSID601031470
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | |||
|
G1TI012DLT
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
